Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This ...

The IL-23 pathway is already targeted by various injectable antibody-based drugs, including AbbVie's own Skyrizi (risankizumab) – which is FDA-approved for plaque psoriasis, psoriatic arthritis ...

He brings to mind words that Christ would speak many years in the future. And he said to them all, If any man will come after Me, let him deny himself, and take up his cross daily, and follow me (Luke ...

DelveInsight's "ENTYVIO Market Size, Forecast, and Market Insight Report" highlights the details around ENTYVIO, a gut-selective biologic developed by Takeda Pharmaceutical. The report provides ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Protagonist Therapeutics, Inc.’s PTGX share price has surged by 6.71%, which has investors questioning if this is right time to sell.

SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a ...

The divide between firefighters and fire department leadership is nothing new. But what causes such rifts, and how can they ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.